SG10202106462TA - Combination therapy for cancer treatment - Google Patents
Combination therapy for cancer treatmentInfo
- Publication number
- SG10202106462TA SG10202106462TA SG10202106462TA SG10202106462TA SG10202106462TA SG 10202106462T A SG10202106462T A SG 10202106462TA SG 10202106462T A SG10202106462T A SG 10202106462TA SG 10202106462T A SG10202106462T A SG 10202106462TA SG 10202106462T A SG10202106462T A SG 10202106462TA
- Authority
- SG
- Singapore
- Prior art keywords
- combination therapy
- cancer treatment
- cancer
- treatment
- therapy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662331253P | 2016-05-03 | 2016-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202106462TA true SG10202106462TA (en) | 2021-07-29 |
Family
ID=60203338
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202106462TA SG10202106462TA (en) | 2016-05-03 | 2017-05-03 | Combination therapy for cancer treatment |
| SG11201809606YA SG11201809606YA (en) | 2016-05-03 | 2017-05-03 | Combination therapy for cancer treatment |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809606YA SG11201809606YA (en) | 2016-05-03 | 2017-05-03 | Combination therapy for cancer treatment |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190151331A1 (ru) |
| EP (1) | EP3452060A4 (ru) |
| JP (2) | JP2019514962A (ru) |
| KR (2) | KR20230075528A (ru) |
| CN (1) | CN109414454A (ru) |
| AU (2) | AU2017260425B2 (ru) |
| BR (1) | BR112018072560A2 (ru) |
| CA (1) | CA3022699A1 (ru) |
| CL (1) | CL2018003123A1 (ru) |
| EA (1) | EA201892510A3 (ru) |
| IL (3) | IL300085A (ru) |
| MX (1) | MX2018013354A (ru) |
| SG (2) | SG10202106462TA (ru) |
| WO (1) | WO2017192740A2 (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2725023T3 (es) | 2006-10-12 | 2019-09-18 | Galera Labs Llc | Métodos para el tratamiento de la mucositis oral |
| WO2013048965A1 (en) | 2011-09-26 | 2013-04-04 | Galera Therapeutics, Llc | Methods for treatment of diseases |
| RS60558B1 (sr) | 2015-08-11 | 2020-08-31 | Galera Labs Llc | Pentaaza makrociklični prstenasti kompleksi koji poseduju oralnu bioraspoloživost |
| SG11201809126RA (en) | 2016-05-03 | 2018-11-29 | Bayer Pharma AG | Aromatic sulfonamide derivatives |
| US11219614B2 (en) | 2016-09-01 | 2022-01-11 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound |
| IL269915B (en) | 2017-04-13 | 2022-09-01 | Galera Labs Llc | Cancer immunotherapy combined with a macrocyclic ring pentase complex |
| WO2019098288A1 (ja) * | 2017-11-15 | 2019-05-23 | 学校法人 慶應義塾 | 抗腫瘍剤及び配合剤 |
| US20200397817A1 (en) * | 2017-11-30 | 2020-12-24 | SHIEH, Darbin | Method for predicting and modulating susceptibility of cancer cell to programmed cell death |
| GB201800733D0 (en) * | 2018-01-17 | 2018-02-28 | Cambridge Entpr Ltd | Cancer |
| JP2019131508A (ja) * | 2018-01-31 | 2019-08-08 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 |
| WO2019152661A1 (en) * | 2018-01-31 | 2019-08-08 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent |
| WO2019232648A1 (en) * | 2018-06-08 | 2019-12-12 | Atomic Energy Of Canada Limited / Énergie Atomique Du Canada Limitée | Use of a checkpoint inhibitor in combination with ultralow dose whole body irradiation |
| CN109620836B (zh) * | 2018-12-24 | 2021-05-18 | 陕西科技大学 | 一种具有抗乳腺癌作用的复方药物组合物及其用途和基于此组合物的药物 |
| WO2021050490A1 (en) * | 2019-09-13 | 2021-03-18 | The Trustees Of Columbia University In The City Of New York | Methods of enhancing radiotherapy using ferroptosis inducers as radiosensitizers |
| CN114502179A (zh) * | 2019-10-10 | 2022-05-13 | 加莱拉实验室有限责任公司 | 含锰配合物的水性制剂的制备方法、制剂和治疗方法 |
| EP4157242A1 (en) * | 2020-06-02 | 2023-04-05 | Galera Labs, LLC | Combination cancer therapy with pentaaza macrocyclic ring complex and hormone therapy agent |
| WO2022026753A1 (en) * | 2020-07-29 | 2022-02-03 | University Of Kentucky Research Foundation | Gold(iii) compounds and cancer cell-selective modulation of mitochondrial respiration and metabolism |
| WO2024026273A1 (en) * | 2022-07-25 | 2024-02-01 | Galera Labs, Llc | Therapy for reduced ototoxicity from chemotherapeutic agent with pentaaza macrocyclic ring complex |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2859916B1 (en) * | 2008-05-22 | 2017-11-29 | Galera Labs, LLC | Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy |
| WO2010049182A2 (en) * | 2008-10-29 | 2010-05-06 | Istituto Superiore Di Sanitá | Treatment of retroviral reservoirs exploiting oxidative stress |
| WO2013048965A1 (en) * | 2011-09-26 | 2013-04-04 | Galera Therapeutics, Llc | Methods for treatment of diseases |
-
2017
- 2017-05-03 BR BR112018072560-9A patent/BR112018072560A2/pt not_active Application Discontinuation
- 2017-05-03 SG SG10202106462TA patent/SG10202106462TA/en unknown
- 2017-05-03 EP EP17793268.8A patent/EP3452060A4/en not_active Withdrawn
- 2017-05-03 SG SG11201809606YA patent/SG11201809606YA/en unknown
- 2017-05-03 IL IL300085A patent/IL300085A/en unknown
- 2017-05-03 JP JP2018557923A patent/JP2019514962A/ja active Pending
- 2017-05-03 CA CA3022699A patent/CA3022699A1/en active Pending
- 2017-05-03 CN CN201780041021.XA patent/CN109414454A/zh active Pending
- 2017-05-03 KR KR1020237017299A patent/KR20230075528A/ko not_active Application Discontinuation
- 2017-05-03 EA EA201892510A patent/EA201892510A3/ru unknown
- 2017-05-03 WO PCT/US2017/030871 patent/WO2017192740A2/en active Application Filing
- 2017-05-03 MX MX2018013354A patent/MX2018013354A/es unknown
- 2017-05-03 US US16/098,026 patent/US20190151331A1/en active Pending
- 2017-05-03 AU AU2017260425A patent/AU2017260425B2/en active Active
- 2017-05-03 KR KR1020187034451A patent/KR20180132939A/ko active Application Filing
-
2018
- 2018-10-29 IL IL262661A patent/IL262661B/en unknown
- 2018-10-31 CL CL2018003123A patent/CL2018003123A1/es unknown
-
2022
- 2022-01-26 IL IL290149A patent/IL290149A/en unknown
-
2023
- 2023-01-05 JP JP2023000572A patent/JP2023036950A/ja active Pending
- 2023-07-05 AU AU2023204318A patent/AU2023204318A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180132939A (ko) | 2018-12-12 |
| SG11201809606YA (en) | 2018-11-29 |
| IL290149A (en) | 2022-03-01 |
| JP2023036950A (ja) | 2023-03-14 |
| AU2017260425B2 (en) | 2023-04-06 |
| IL262661B (en) | 2022-03-01 |
| CA3022699A1 (en) | 2017-11-09 |
| CN109414454A (zh) | 2019-03-01 |
| IL300085A (en) | 2023-03-01 |
| MX2018013354A (es) | 2019-02-20 |
| JP2019514962A (ja) | 2019-06-06 |
| EA201892510A3 (ru) | 2019-09-30 |
| CL2018003123A1 (es) | 2019-05-03 |
| EA201892510A2 (ru) | 2019-06-28 |
| AU2023204318A1 (en) | 2023-07-27 |
| KR20230075528A (ko) | 2023-05-31 |
| BR112018072560A2 (pt) | 2019-02-19 |
| US20190151331A1 (en) | 2019-05-23 |
| AU2017260425A1 (en) | 2018-11-22 |
| WO2017192740A2 (en) | 2017-11-09 |
| IL262661A (en) | 2018-12-31 |
| EP3452060A2 (en) | 2019-03-13 |
| EP3452060A4 (en) | 2020-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290149A (en) | Combined treatment for cancer | |
| HK1247129A1 (zh) | 治療癌症的聯合療法 | |
| IL254705B (en) | Combined treatment for cancer | |
| IL255060A0 (en) | Combined treatment for cancer | |
| HK1251475A1 (zh) | 用於癌症治療的聯合療法 | |
| EP3180010A4 (en) | Combination therapy for treating cancer | |
| PT3423087T (pt) | Terapia de cpombinação contra o cancro | |
| EP3407978A4 (en) | COMBINATION THERAPY FOR TREATING CANCER | |
| IL267795A (en) | Combined treatment for cancer | |
| EP3258965A4 (en) | Combination therapy for cancer treatment | |
| HK1258319A1 (zh) | 癌症療法 | |
| IL263802A (en) | Combinations of cancer treatments | |
| EP3193884A4 (en) | Combination therapy for treating cancer | |
| IL274837B1 (en) | Combined treatment for cancer | |
| IL266993A (en) | Combined therapy for cancer treatment | |
| HK1251794A1 (zh) | 癌症治療 | |
| IL258494A (en) | Rational combined therapy for cancer treatment | |
| HK1254687A1 (zh) | 用於癌症的聯合療法 | |
| IL253642A0 (en) | Combined treatment for cancer | |
| HRP20210383T8 (hr) | Kombinirana terapija za rak | |
| GB201601248D0 (en) | Cancer therapy |